This database contains 438 studies, archived under the term: "USA"
Click here to filter this large number of results.
Learning in Alzheimer’s disease is facilitated by social interaction
Seminal work in Gary Van Hoesen’s laboratory at Iowa in the early 1980s established that the hallmark neuropathology of Alzheimer’s disease (AD; neurofibrillary tangles) had its first foothold in specific parts of the hippocampal formation and entorhinal cortex, effectively isolating the hippocampus from much of its input and output and causing the distinctive impairment of […]
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]
The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline
Donohue, Michael C.,
Sperling, Reisa A.,
Salmon, David P.,
Rentz, Dorene M.,
Raman, Rema,
Thomas, Ronald G.,
Weiner, Michael,
Aisen, Paul S
Importance: As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. Objective: To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
A telephone-delivered psychosocial intervention improves dementia caregiver adjustment following nursing home placement
Objective: Study the preliminary efficacy of a telephone intervention, Family Intervention: Telephone Tracking-Nursing Home (FITT-NH) for improving dementia caregivers’ adjustment following nursing home placement.; Methods: Caregivers were enrolled on average 6 weeks following the care-recipients’ placement in a nursing home. Baseline assessment included self-report measures of caregiver emotional functioning, staff-caregiver interactions, placement satisfaction, health-related quality […]
A videophone psychosocial intervention for dementia caregivers
Background/objectives: Available services and intervention programs for dementia caregivers are often underutilized because of issues such as cost, logistics, lack of knowledge about available services, or insufficient support from others. Information technologies offer the potential of removing these barriers and facilitating the ability of caregivers to access needed support. This project evaluated the feasibility and […]